Recent Analysts’ Ratings Updates for LeMaitre Vascular (LMAT)

Several analysts have recently updated their ratings and price targets for LeMaitre Vascular (NASDAQ: LMAT):

• 2/26/2026 – LeMaitre Vascular had its price target raised by Barrington Research from $95.00 to $105.00. They now have an “outperform” rating on the stock.
• 2/26/2026 – LeMaitre Vascular had its “buy” rating reaffirmed by Roth Mkm. They now have a $117.00 price target on the stock, up from $108.00.
• 2/26/2026 – LeMaitre Vascular had its price target raised by Wells Fargo & Company from $87.00 to $94.00. They now have an “equal weight” rating on the stock.
• 2/26/2026 – LeMaitre Vascular had its price target raised by Citizens Jmp from $113.00 to $118.00. They now have a “market outperform” rating on the stock.
• 2/24/2026 – LeMaitre Vascular was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 2/21/2026 – LeMaitre Vascular was upgraded by Wall Street Zen from “hold” to “buy”.
• 2/20/2026 – LeMaitre Vascular had its “outperform” rating reaffirmed by Barrington Research. They now have a $95.00 price target on the stock.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th will be paid a $0.25 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, March 12th. LeMaitre Vascular’s payout ratio is presently 31.87%.

Insider Activity

In other news, CEO George W. Lemaitre sold 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $106.76, for a total value of $16,014,000.00. Following the transaction, the chief executive officer owned 1,532,304 shares in the company, valued at $163,588,775.04. This trade represents a 8.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Trent G. Kamke sold 1,044 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the transaction, the insider owned 6,677 shares in the company, valued at $736,406.33. This represents a 13.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 215,438 shares of company stock valued at $23,062,911. 9.50% of the stock is currently owned by insiders.

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.